Relapse Clinical Trials in Shanghai, Shanghai Municipality
28 recruitingShanghai, Shanghai Municipality, China
Showing 1–20 of 28 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 1
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital27 enrolled4 locationsNCT06326021
Recruiting
Phase 1Phase 2
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT06316856
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 1Phase 2
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia+1 more
Beijing GoBroad Hospital80 enrolled4 locationsNCT06316427
Recruiting
Phase 1Phase 2
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT07070323
Recruiting
Phase 1
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Refractory AMLRelapsed Adult AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine24 enrolled1 locationNCT06307054
Recruiting
Phase 1
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 3
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.324 enrolled19 locationsNCT06082102
Recruiting
Phase 2
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.100 enrolled11 locationsNCT04684147
Recruiting
Early Phase 1
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital24 enrolled1 locationNCT06718270
Recruiting
Phase 4
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital8 enrolled1 locationNCT05806580
Recruiting
Early Phase 1
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.9 enrolled1 locationNCT06541444
Recruiting
Early Phase 1
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.9 enrolled1 locationNCT06541405
Recruiting
Phase 1
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited60 enrolled2 locationsNCT06445517
Recruiting
Phase 1
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Acute Lymphoblastic Leukemia, in RelapseB-cell Lymphoma RecurrentB-cell Lymphoma Refractory+1 more
Rong Tao48 enrolled2 locationsNCT06445803
Recruiting
Phase 1Phase 2
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
Aibin Liang，MD，Ph.D.48 enrolled1 locationNCT05842707